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a b s t r a c t
Vaccination is the primary strategy for the prevention and control of inﬂuenza outbreaks. However, the
manufacture of inﬂuenza vaccine requires a high-yield seed strain, and the conventional methods for
generating such strains are time consuming. In this study, we developed a novel method to rapidly
generate high-yield candidate vaccine strains by integrating error-prone PCR, site-directed mutagenesis
strategies, and reverse genetics. We used this method to generate seed strains for the inﬂuenza A(H1N1)
pdm09 virus and produced six high-yield candidate strains. We used a mouse model to assess the
efﬁcacy of two of the six candidate strains as a vaccine seed virus: both strains provided complete
protection in mice against lethal challenge, thus validating our method. Results conﬁrmed that the
efﬁcacy of these candidate vaccine seed strains was not affected by the yield-optimization procedure.
& 2015 Elsevier Inc. All rights reserved.
Introduction
Inﬂuenza viruses cause occasional pandemics and seasonal epi-
demics, thus presenting continuous challenges to public health.
Vaccination is the primary strategy used to slow and stop transmission
of the virus and to reduce the effect of the disease. A high-yield
vaccine seed strain is required for vaccine manufacturing and, thus, is
key to a successful inﬂuenza vaccination program. However, it is not
uncommon that strains recommended as inﬂuenza vaccine strains by
the World Health Organization (WHO) have low yields in chicken
embryonic eggs (hereafter referred to as eggs) (Gerdil, 2003). Low-
yield strains must be engineered into high-yield strains, a process that
can be time consuming and, thus, signiﬁcantly delay vaccine produc-
tion. Almost three months were required for the WHO collaborative
laboratories and vaccine companies to generate suitable vaccine
strains to produce vaccine against the 2009 pandemic inﬂuenza virus,
A(H1N1)pdm09 (Chen et al., 2010; Robertson et al., 2011). Without
this delay, the vaccine could have lessened the effect of the pandemic's
second wave of infection and reduced the number of associated
deaths. Thus, the ability to rapidly generate high-yield vaccine strains
is a critical factor in preventing and controlling inﬂuenza outbreaks.
Two common strategies have been used to generate inﬂuenza
vaccine seed viruses: 1) co-infection of a cell or an egg with two
viruses, one with high-yield features and another with antigeni-
cally matched hemagglutinin and neuraminidase (Kilbourne, 1969;
Kilbourne and Murphy, 1960); and 2) reverse genetics to generate a
virus with antigenically matched hemagglutinin and neuraminidase,
and internal genes from another virus as backbone, which help
improve yields (Fodor et al., 1999; Horimoto et al., 2007; Neumann
et al., 1999; Nicolson et al., 2005). During the past decades, the co-
infection method has been used widely to generate vaccine seed
viruses. The disadvantage of co-infection is that the reassortment
events cannot be well controlled and may lead to viruses with
undesired traits (Fulvini et al., 2011; Ottmann et al., 2010). Thus, instead
of co-infection, egg adaption is often used to improve seed virus
growth in eggs (Gambaryan et al., 1999; Robertson et al., 1987; Rogers
et al., 1983;Widjaja et al., 2006). In contrast to the co-infectionmethod,
the reverse genetics method can deﬁne the genomic constellation
(Fodor et al., 1999; Horimoto et al., 2007; Neumann et al., 1999;
Nicolson et al., 2005). However, it is difﬁcult to generate a high-yield
seed strain if the hemagglutinin and neuraminidase are not compatible
with the other six gene segments from the backbone virus, and this
method does not readily allow for selecting different combinations of
gene segments that may result in higher yield viruses. In recent years, a
recombinant technique has been used to increase the yields of
inﬂuenza vaccine candidates (Adamo et al., 2009; Gomila et al., 2013;
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Harvey et al., 2011; Harvey et al., 2010; Jing et al., 2012; Pan et al., 2012).
These reassortants, which have chimeric hemagglutinin or neuramini-
dase, had considerably more seed virus growth in eggs or Madin-Darby
canine kidney (MDCK) cells. However, these methods usually require
weeks to generate a desired strain with high yields.
In this study, we developed a novel error-prone PCR (epPCR)–
based mutagenesis approach to rapidly generate high-yield inﬂu-
enza vaccine strains.
Results
epPCR-based mutagenesis approach
In this study, we developed an epPCR-based mutagenesis
strategy for generating high-yield inﬂuenza vaccine candidates
(Fig. 1). In this method, the epPCR products are used directly as
primers for site-directed mutagenesis, and individual cloned
plasmids are then extracted. Viruses are rescued by using the
individual selected plasmids, and the rescued viruses are screened
for a phenotype of high yield in eggs.
To validate our method, we used the hemagglutinin of CA/04 as
the template to generate high-yield vaccine candidates. We ﬁrst
applied epPCR to breed the regions of receptor-binding sites: one
region covered the 130 loop and 190 helix of the hemagglutinin
gene (referred to as 130loopþ190helix), and the other region
covered the 190 helix and 220 loop of the hemagglutinin gene
(referred to as 190helixþ220loop). The epPCR products (234 bp
for 130loopþ190helix; 171 bp for 190helixþ220loop) were sub-
sequently used as primers in site-directed mutagenesis.
Broad diversity of the hemagglutinin mutants generated by the
epPCR-based mutagenesis strategy
To evaluate the proﬁle of the hemagglutinin mutant library, we
sequenced a total of 292 clones (142 for 130loopþ190helix; 150
for 190helixþ220loop). Of the 292 clones, 111 carried at least one
amino acid mutation while maintaining the correct open-reading
frame. Of these 111 hemagglutinin mutants, 66 were derived from
the 130loopþ190helix epPCR products, and 45 were derived from
the 190helixþ220loop epPCR products. Ninety-eight of these 111
hemagglutinin mutants had a single amino acid mutation, eight
had double mutations, and ﬁve had triple mutations. Except for
two clones with the same mutations, all hemagglutinin mutants
carried different mutations (Supplementary Table S1). The muta-
tion proﬁle analysis demonstrated that the mutated sites broadly
spanned the entire target region from the 130loop to the 220loop.
Of note, some of these mutations (V135I, A137T, P140L, H141Q,
S146G, V155I, K156E, N159K, G173R, V176I, A189T, T200S, K212T,
I219V) were observed in the hemagglutinin gene of the A(H1N1)
pdm09 virus ﬁeld strains.
To further demonstrate the diversity of the mutant library, we
used next-generation sequencing to sequence the plasmid library
generated by 130loopþ190helix epPCR products. The readings
showed that 63.8% of the sequences had nucleotide changes, and
83.9% of those led to effective amino acid mutations with correct
open-reading frames. The mutations were distributed among the
130loop and the 190helix at both the nucleotide and amino acid
levels (Supplementary Fig. S1).
Rapid generation of higher yield strains by using the epPCR-based
mutagenesis strategy
To determine if seed strains with high yield could be directly
rescued from the 111 mutants, we recovered the highest-yield
viruses by transfection, inoculated them into 10-day-old eggs, and
subsequently determined HA titers for comparisonwith the HA titers
for the wild-type virus. The wild-type virus had an HA titer of 32, and
six mutants (nos. 22, 58, 79, 81, 88, and 114) had an HA titer of at
least 128 in passage one (Table 1). Of note, the HA titers of the wild-
type virus remained stable at 32 in passages two and three, but the
Fig. 1. Overall strategy for generating a hemagglutinin mutant library. Based on this method, chicken embryonic egg–propagated seed viruses with high yield can be selected
for inﬂuenza vaccine candidate strains. The 130loopþ190helix or 190helixþ220loop in hemagglutinin gene of inﬂuenza A/California/04/09 (H1N1) virus are ampliﬁed by
error-prone PCR (epPCR) by using a GeneMorph II Random Mutagenesis Kit (Agilent Technologies, Santa Clara, CA) (step 1). epPCR products are then used as primers in the
site-directed mutagenesis (step 2). After DpnI digestion at 37 1C for 1 h (step 3), the PCR product is transformed into XL1-Blue Supercompetent Cells (Agilent Technologies,
Santa Clara, CA), and the cells are inoculated onto LB (Luria Bertani) plates or into LB medium (step 4). The individual plasmid or plasmid library is then extracted (step 5) and
used with 6 internal genes from A/Puerto Rico/8/1934(H1N1) and the neuraminidase gene from CA/04 to rescue viruses (step 6). Rescued viruses are inoculated into 10-day-
old chicken embryonic eggs to generate high-yield vaccine seed. The steps are indicated by circled numbers in the ﬁgure.
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titers of mutant viruses number 81 and 88 increased to 512 after
passage two and three, respectively (Table 1).
Viral growth kinetics demonstrated that these six hemaggluti-
nin mutants replicated more efﬁciently than the wild-type virus in
MDCK cells (Fig. 2A). The peak HA titers of these viruses reached
128–512 in MDCK cells, but the peak titer was only 32 for the wild-
type virus. Among these six mutants, numbers 22 and 81 yielded
the highest HA titer (512) in MDCK cells. The peak TCID50 of these
mutants was 0.4–1.0 log10 TCID50 higher than that for wild-type
virus (Fig. 2A).
The Western blot assay results for cell lysate tested 72 h and
96 h after inoculation conﬁrmed these results. Nucleoprotein
expression for the mutant viruses was stronger than that for the
wild-type strain. The nucleoprotein expression level for mutants
number 22, 58, 79, 81, 88, and 114 were 2.0-, 1.4-, 1.9-, 2.8-, 1.6-,
and 1.7-fold higher, respectively, than that for the wild-type virus
(Fig. 2B).
Consistent with our HA assay results, qPCR results for the six
selected mutants showed higher yields than those for the wild-
type virus. On average, viral RNA levels in allantoic ﬂuid of eggs
inoculated with mutants number 22, 58, 79, 81, 88 and 114 were
4.3-, 2.3-, 12.3-, 64.6-, 30.9-, and 30.9-fold (copies/μl) higher,
respectively, than levels in allantoic ﬂuid of eggs inoculated with
the wild-type strain (Fig. 3). The total protein concentrations of
mutants number 22, 58, 79, 81, 88 and 114 were 1.90-, 2.33-, 1.99-,
2.50-, 1.30- and 1.97-fold (μg/ml) higher, respectively, than that of
the wild-type strain (Fig. 4). These results further conﬁrmed that,
compared with the wild-type virus, the six selected mutants
generated by the epPCR-based mutagenesis strategy grew more
efﬁciently in eggs.
One-way HI assays using post-infection ferret antiserum raised
against CA/04 showed that the homologous HI titers of 3200 for
CA/04 (Table 1). The heterologous HI titers of the six mutant
viruses were 3200 or 1600, demonstrating that these candidates
had few antigenic differences from the wild-type strain.
High-yield vaccine candidates providing full protection against lethal
challenge in mice
To conﬁrm that our mutagenesis approach had not affected
subsequent vaccine efﬁcacy, we selected the two mutants with the
highest HA titers (mutants nos. 81 and 88) as vaccine candidates
and evaluated their efﬁcacy in a mouse model. Serum samples
collected from vaccinated mice 2 weeks after the booster vaccine
was administered exhibited HI titers substantially higher than
those for the mock-vaccinated group (Table 2). After viral chal-
lenge, virus replication (reaching levels up to 105.4TCID50/ml) was
detected in the lungs of all mock-vaccinated mice; no virus was
detected in any of the vaccinated mice (Table 2). Mice in the
mutant number 81– and 88–vaccinated groups did not lose
weight, but the mock-vaccinated mice were lethargic and rapidly
lost weight (Fig. 5A). All vaccinated mice survived the lethal
challenge; all mock-vaccinated mice died 7 days after challenge
(Fig. 5B).
Photomicrographs of hematoxylin and eosin–stained lung sec-
tions are shown in Fig. 6. Mock-vaccinated mice displayed acute,
diffuse, necrotizing bronchitis and bronchiolitis 4 days after challenge
Table 1
Characterization of inﬂuenza A(H1N1)pdm09 vaccine candidates generated by using an error-prone PCR–based mutagenesis strategy.
Virus HA titera, passage no. HI titerb, passage no. Mutation (residue no.)c
1 2 3 1 2 3
Wild type 32 32 32 3200 3200 3200 –
Mutant, d no.
22 128 256 256 3200 3200 3200 K133N (130), V178M (175)
58 128 256 128 3200 3200 3200 K149E (146)
79 128 128 256 3200 3200 1600 K157I (154)
81 128 128 512 1600 1600 1600 K133I (130)
88 256 512 256 1600 1600 3200 K157I (153), I169T (166)
114 256 128 256 3200 3200 3200 K212T (209)
a HA, hemagglutination.
b HI, hemagglutination inhibition. Titers were determined by using ferret serum (anti-CA/04).
c Mutations in the hemagglutinin protein sequence of the mutant, H3 numbering; the residue numbers are residues in the hemagglutinin of inﬂuenza A(H1N1)
pdm09 virus.
d Reverse genetics–derived viruses were generated by using hemagglutinin of wild-type inﬂuenza A/California/04/09 (H1N1) virus (CA/04) virus or hemagglutinin
mutants derived from error-prone PCR, neuraminidase of CA/04, and six other gene segments (polymerases PA [polymerase acidic subunit], PB1 [polymerase basic subunit
1], and PB2 and nucleoprotein, matrix protein, and nonstructural protein) from inﬂuenza A/PR/8/34(H1N1) virus.
Fig. 2. Characterization of the high-yield inﬂuenza A(H1N1)pdm09 vaccine candi-
dates generated by using the error-prone PCR–based mutagenesis strategy. Viruses
were inoculated into Madin-Darby canine kidney cells at a multiplicity of infection
of 0.001. (A) Growth curves for wild-type (WT) and mutant viruses (nos. 22, 58, 79,
81, 88, and 144) measured by 50% tissue culture infectious dose (TCID50; values
shown below columns) at various hours after infection (hpi). (B) Western blot
showing the nucleoprotein expression level for the WT and mutant viruses (viruses
shown above columns).
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(Fig. 6C). No histopathologic changes were observed in the mice
vaccinated with mutants number 81 or 88 (Fig. 6), demonstrating
effective protection of both vaccine candidates from the lethal
mouse-adapted CA/04 challenge. Thus, our results indicate that the
high-yield candidate vaccines generated by our epPCR-based muta-
genesis strategy did not have altered antigenicity and could serve as
potential seed strains for the manufacture of inﬂuenza vaccines.
Receptor-binding models of improved-yield mutants
Among the six mutation sites, only mutants number 22 and 81
had residue 133 located in the receptor-binding sites of hemag-
glutinin (Supplementary Fig. S2). These crystal structures of the
bindings between the hemagglutinin of inﬂuenza A(H1N1)pdm09
and glycan analogs 6SLN or 3SLN were used in computational
mutation simulations to study the effects of amino acid modiﬁca-
tions on hemagglutinin-receptor bindings.
As measurements of binding modiﬁcations caused by mutations,
we calculated the distances between the oxygen atom of a water
molecule (which formed a hydrogen bond between amino acid
residue 133 and glycan receptors) and the nearest atoms of sialic
acid and the distances between the oxygen atom of a water molecule
and residue 133. Moreover, as a quantiﬁcation of hemagglutinin–
glycan binding avidities, we obtained the PoseScore (Fan et al., 2011)
for structural interactions between glycans and all wild-type and
computationally mutated hemagglutinin structures (Fig. 7).
When the hemagglutinin bound to 3SLN, the wild-type struc-
ture with a polar and positively charged lysine at residue 133 had a
distance of 4.57 Å to the linker water molecule, and the whole
interaction had a PoseScore of 6.32 (Fig. 7B). The K133N mutant
had a polar, but neutral, asparagine at residue 133, which was only
2.23 Å from the linker water molecule, and its PoseScore wass
7.04 (Fig. 7D). The K133I mutant had a nonpolar and neutral
isoleucine at residue 133, which was 2.95 Å to the linker water
molecule, and its PoseScore was 6.88 (Fig. 7F). These results
showed that both the contact distances and pose binding scores
were decreased by substituting a charged lysine with neutral
asparagine or isoleucine. Thus, given that smaller contact dis-
tances and lower PoseScores suggest stronger interactions
between glycans and proteins, mutations K133N and K133I could
lead to increased 3SLN bindings compared with what the wild-
type strain does. These stronger hemagglutinin–3SLN bindings for
mutants number 22 and 81, compared with that for the wild type
strain, may contribute to the higher replication efﬁciencies of
these two mutants in eggs and MDCK cells.
Of interest, the structural simulation showed that both the
contact distances and pose binding scores between hemagglutinin
and 6SLN were also decreased by substituting a charged lysine
with neutral asparagine or isoleucine. When the hemagglutinin
bound to 6SLN, the wild-type structure with a polar and positively
charged lysine at residue 133 had a distance of 4.41 Å to the linker
water molecule and the whole interaction had a PoseScore of
11.83 (Fig. 7A). The K133N mutant had a polar but neutral
asparagine, which wass only 2.04 Å from the linker water mole-
cule, and its PoseScore wass 12.18 (Fig. 7C). The K133I mutant
had a nonpolar and neutral isoleucine at residue 133, which was
2.82 Å from the linker water molecule, and its PoseScore was
14.42 (Fig. 7E). These results suggested that mutations K133N
and K133I could lead to stronger 6SLN bindings in mutants
number 88 and 81 than in the wild-type virus.
Discussion
Conventional site-directed mutagenesis strategies depend on
virus variants that are manually selected and usually have a single
or a few mutations; egg-adaptation strategy depends on the virus
Fig. 3. Quantiﬁcation of wild-type (WT) and mutant viruses propagated in eggs as
determined by using a hemagglutinin gene–speciﬁc quantitative reverse transcrip-
tion PCR method. Results are expressed as the median (horizontal bars) RNA copy
number (1 μl cDNA)7SD (vertical bars).
Fig. 4. Total protein quantiﬁcation of wild-type (WT) and mutant viruses that
puriﬁed from the allantoic ﬂuids of 11-day-old embryonated chicken eggs. Results
are expressed as the median (horizontal bars) protein concentration 7SD
(vertical bars).
Table 2
Pathogenesis and immunologic responses in vaccinated mice challenged with mouse-adapted inﬂuenza A/California/04/09 (H1N1) virus.
Vaccine group Log10TCID50/ml, mean7SDa log2HI titer, mean7SDb log2HI titer, mean7SDc
Mutant no. (mutation)
81 (K133I) Below detection limit 8.3270.70 8.1270.45
88 (K157I, I169T) Below detection limit 8.1270.45 8.1270.45
Mock 5.470.1 Below detection limit Below detection limit
a Groups of BALB/c mice were inoculated intranasally under light anesthesia with 10 the 50% lethal dose of mouse-adapted CA/04 virus. Three mice from each group
were euthanized on day 4 after virus challenge, and virus titers in lungs were determined by TCID50 (50% tissue culture infectious dose) in MDCK cells.
b Serum samples were collected 2 weeks after the booster vaccine was administered, and antibody response levels against the immunogen mutant were measured by
using the HI (hemagglutination inhibition) assay.
c Serum samples were collected 2 weeks after the booster vaccine was administered, and antibody response levels against the wide type were measured by using the HI
(hemagglutination inhibition) assay.
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variants generated by error in natural viral RNA replication (viral
quasispecies) resulting from the lack of proofreading capacity in
viral RNA polymerase. The small pool of virus variants produced by
these approaches is a bottleneck in the process of selecting high-
yield seed strains for inﬂuenza vaccine production. Thus, we
hypothesized that the in vitro breeding of a diverse inﬂuenza virus
variant library by epPCR would enhance the process for generating
high-yield strains. The epPCR method has been widely used to
generate libraries of mutant proteins for phenotype selection
(Cherry et al., 1999; Cirino et al., 2003; Daugherty et al., 2000;
Wan et al., 1998; Zang et al., 2006). By integrating epPCR, site-
directed mutagenesis, and reverse genetics, we developed a novel
strategy for rapidly generating high-yield vaccine candidates. Our
data show that this strategy allows for the rapid generation of
high-yield vaccine candidates for the A(H1N1)pdm09 virus.
Whole-virus inactivated vaccines derived from two high-yield
candidates that we generated provided full protection against
lethal A(H1N1)pdm09 virus challenge in mice.
In a recent study, an epPCR strategy was developed to generate
inﬂuenza mutant library for phenotype selection (Imai et al., 2012;
Wu et al., 2013). In these studies, the epPCR was used to amplify
the partial HA or whole NA genes, and the ampliﬁed fragment or
gene need to be digested with restriction enzyme and then
subcloned to a plasmid for virus rescuing using reverse genetics.
Unlike their approaches for generating inﬂuenza mutant library,
our strategy integrated the epPCR and site mutagenesis approach
by using the epPCR product directly as primers for site mutagen-
esis. Therefore, through two single PCRs, one epPCR and another
site mutagenesis PCR, we can target any region of an inﬂuenza
gene segment to generate plasmid mutant library without design-
ing any restriction enzyme site. Such a strategy allows us to skip
the subcloning step, which is required by the methods described
in Imai et al., 2012 and Wu et al., 2013. Therefore, our approach
developed here would be much less labor intensive and more
efﬁcient. It is worth mentioning that our method can potentially
be used for generating mutant libraries for phenotype selection for
not only inﬂuenza virus but also many other microbes.
The mechanism(s) by which the mutations in the hemaggluti-
nin gene improve virus replication are poorly understood. Pre-
vious studies suggested that the functional balance between
receptor binding of the hemagglutinin and the receptor-releasing
property of the neuraminidase is critical for efﬁcient replication of
inﬂuenza viruses (Mitnaul et al., 2000; Wagner et al., 2002).
Mutations near the receptor-binding sites of the hemagglutinin
are known to affect the replication abilities of viruses (Chen et al.,
2010; Hartgroves et al., 2010; Lugovtsev et al., 2005; Robertson et
al., 2011). In this study, we constructed a hemagglutinin plasmid
library targeted to the receptor-binding sites of inﬂuenza A(H1N1)
pdm09 virus. By using the cloned mutant hemagglutinin genes, we
successfully rescued 43 viruses without subsequent egg passages.
Of these 43 viruses, six mutants had improved yields in eggs.
Among the mutations in the hemagglutinin of the six selected
vaccine candidates in our study (Table 1), mutations K157I and K212T
were previously reported in the high-yield A(H1N1)pdm09 vaccine
strains generated in eggs (Robertson et al., 2011). Identiﬁcation of
these two previously reported mutations, which improved the yields
of A(H1N1)pdm09 virus, validates the effectiveness of our strategy.
Our strategy is further validated by the fact that we also found some
novel sites in the hemagglutinin that improved yields without
changing virus antigenicity. For example, K133, which was found in
two high-yield mutants, is absent in the hemagglutinin of the
contemporary human seasonal inﬂuenza A(H1N1) virus and is highly
conserved in both the A(H1N1)pdm09 virus and its precursor, the
hemagglutinin gene of the 1918 pandemic H1N1 inﬂuenza virus. The
K133N HA mutation was predicted to broadly change the electro-
static potentials surrounding the receptor-binding domain (Li et al.,
2013). As shown in receptor-binding models (Fig. 7), the substitution
of a positively charged lysine in position 133 by a polar uncharged
asparagine or hydrophobic isoleucine could contribute to the
increase in binding avidity and be responsible for the improved yield
of these mutants in eggs and MDCK cells.
A previous study predicted the important role of K133 and
K149 in receptor-binding afﬁnity and in the virulence of A(H1N1)
pdm09 virus (Meroz et al., 2011). Substitution of K133R or K149R
in “swine-like” A(H1N1)pdm09 virus reduced its pathogenicity
(Meroz et al., 2011). The mutants with K133N or K149E mutations
that were identiﬁed in this study have higher yield properties and
may have lower pathogenicity compared with that of the wide-
type strain; which would ensure a safer vaccine production. In
addition, two of six selected mutants with improved yields harbor
K157I mutations. It has been reported that mutants with K157E
mutations are preferred for replication of A/California/7/2009
(H1N1) virus in MDCK cells and eggs (Chen et al., 2010). Our
results also indicate that the presence of a isoleucine residue with
hydrophobic site chain in position 157 of hemagglutinin improves
the growth ability of the A(H1N1)pdm09 virus.
Concerns have been raised that even single amino acid sub-
stitution near receptor-binding sites may change the antigenicity
of inﬂuenza viruses (Koel et al., 2013). However, mutations near
the receptor-binding sites of the hemagglutinin, such as L119I,
A186D, N125D, and D127E, have been used as seed viruses for the
A(H1N1)pdm09 vaccine (Chen et al., 2010). The HI assay results in
our study indicate that the six high-yield candidate vaccine strains
had few antigenic changes from the CA/04 wild-type strain
(Table 1). For example, although K133 was recently documented
to be involved in B cell epitopes recognized by monoclonal
antibodies (Krause et al., 2011; O’Donnell et al., 2012; Whittle
et al., 2011), in our study, mutation K133N did not alter the
antibody-binding avidities of K133N mutant to anti-A(H1N1)
pdm09 virus ferret serum; this ﬁnding has also been reported
elsewhere (Li et al., 2013). Moreover, inactivated vaccines based on
Fig. 5. Protective effect of high-yield vaccine candidates in mice challenged with
mouse-adapted inﬂuenza A/California/04/09 (H1N1) virus. Groups of control;
mock-vaccinated; and mutant number 81–, 88–vaccinated mice were intranasally
inoculated with 10 the 50% lethal dose of virus, after which their body weights
(A) and survival times (B) were monitored for 14 days. Results are shown as the
mean7SD in each group (A).
J. Ye et al. / Virology 482 (2015) 234–243238
two testing candidates that yielded the highest titers in eggs
provided full protection against lethal challenge in experiments
with mice. These results provide further evidence that the epPCR-
based mutagenesis strategy combined with serologic assays, such
as the HI assay, could be used for rapid generation of inﬂuenza
seed viruses.
In summary, we report the use of a novel epPCR-based site-
directed mutagenesis strategy to rapidly generate a diverse inﬂu-
enza hemagglutinin plasmid library and the application of this
method to generate high-yield candidate strains for production of
A(H1N1)pdm09 virus vaccine candidates. The mutations asso-
ciated with high yield in our study could facilitate a quick response
to future outbreaks caused by A(H1N1)pdm09 virus and its
variants. Moreover, this novel strategy could also be applied to
the breeding of other functional regions of a gene to rapidly
generate diverse mutant libraries for gain-of-function studies for
inﬂuenza and potentially other pathogens.
Materials and methods
Cells and viruses
MDCK cells and human embryonic kidney (293T) cells (both
from American Type Culture Collection, Manassas, VA) were used
for propagation and culture of inﬂuenza virus. The cells were
maintained at 37 1C with 5% CO2 in Dulbecco's Modiﬁed Eagle
Medium (GIBCO/BRL, Grand Island, NY) supplemented with 5%
fetal bovine serum (FBS) (Atlanta Biologicals, Lawrenceville, GA),
penicillin–streptomycin, and amphotericin B (GIBCO/BRL, Grand
Island, NY). The wild-type strain of A/California/04/09 (H1N1)
virus (CA/04) was used in the mutant library construction
(Fig. 1); mouse-adapted CA/04 (Ilyushina et al., 2010) was used
for challenge experiments.
All viruses generated by reverse genetics were propagated in
MDCK cells and cultured at 37 1C with 5% CO2 in Opti-MEM medium
(GIBCO/BRL, Grand Island, NY) supplemented with 1 μg/ml of TPCK
(N-tosyl-L-phenylalanine chloromethyl ketone)–Trypsin (Sigma-
Aldrich, St. Louis, MO), penicillin–streptomycin, and amphotericin B
(GIBCO/BRL, Grand Island, NY). Virus titers were determined by 50%
tissue culture infectious dose (TCID50) in MDCK cells.
Primers
Four primers were used in this study: 1) 130loop_F, 50-TCA TGG
CCC AAT CAT GAC TCG AAC-30; 2) 190helix_F, 50-TGG GGC ATT CAC
CAT CCA TCT ACT-30; 3) 190helix_R, 50-AAC ATA TGT ATC TGC ATT
CTG ATA-30; and 4) 220loop_R, 50-TAG TGT CCA GTA ATA GTT CAT
TCT-30. Primers 130loop_F and 190helix_R were used to amplify
the sequence covering the 130-loop and 190-helix of the receptor-
binding site in the hemagglutinin gene of inﬂuenza virus. Primers
190helix_F and 220loop_R were used to amplify the sequence
covering the 190-helix and 220-loop of the receptor-binding site in
the hemagglutinin gene of inﬂuenza virus.
Fig. 6. Histopathologic ﬁndings in hematoxylin and eosin–stained lung samples from vaccinated and mock-vaccinated mice challenged with mouse-adapted inﬂuenza A
(H1N1)pdm09 virus. Four days after challenge, groups of mutant number 81–vaccinated (A), mutant number 88–vaccinated (B), and mock-vaccinated (C) mice were
euthanized, and lungs were collected for histopathologic examination; non-vaccinated, non-challenged mice served as environmental controls (D). A, B, and D) Scale
bar¼100 mm; C) scale bar¼40 mm.
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Fig. 7. The three-dimensional structures of the hemagglutinin of the wild–type (WT) inﬂuenza A/California/04/09 (H1N1) virus and mutant viruses (nos. 22 and 81) in
contact with human-like receptor analog 6SLN (panels A, C, and E) and avian-like receptor analog 3SLN (panels B, D, and F). The protein structures of hemagglutinin are
shown in light gray; residue 133 is in orange. The side chains of interacting residues on the receptor-binding sites are labeled with residue names and locations. The single
letter amino acid annotations were used together with H3 numbering for all binding residues. 6SLN is shown in cyan, and 3SLN is shown in magenta. Red dots indicate the
oxygen atoms from all water molecules that are in contact with hemagglutinin side chains. The distances (in angstroms) between the water molecule and the nearest atom
on both the protein and ligand sides are indicated by dashed lines. (A) WT hemagglutinin with lysine at position 133 in contact with 6SLN. (B) WT hemagglutinin with lysine
at position 133 in contact with 3SLN. (C) K133N mutant hemagglutinin with asparagine at position 133 in contact with 6SLN. (D) K133N mutant hemagglutinin receptor-
binding sites with asparagine at position 133 in contact with 3SLN. (E) Mution K133I at the hemagglutinin receptor-binding site with isoleucine at position 133 in contact
with 6SLN. (F) Mutant K133I with isoleucine at position 133 in contact with 3SLN. Simulations on the hemagglutinin were performed by using the FoldX empirical force ﬁeld
(Schymkowitz et al., 2005), and the structure was visualized by using Chimera (Pettersen et al., 2004); PoseScore (Fan et al., 2011) was used to estimate the likeness of the
WT and mutant protein–glycan binding avidities to that of the native virus.
epPCR-based mutagenesis method to generate hemagglutinin
mutants of inﬂuenza virus
We used the GeneMorph II Random Mutagenesis Kit (Agilent
Technologies, Santa Clara, CA) according to the manufacturer's
instructions to perform epPCR. The resulting products were
used as primers to perform site directed mutagenesis. The
epPCR ampliﬁcation mixture contained 17.75 μl of water, 5 μl
of 10buffer, 1 μl of 2.5 mM deoxyribonucleotide tripho-
sphates, 1 μl of 10 μmol primer (each), 2 μl of hemagglutinin
plasmid of CA/04 (10 pg/μl), and 1 μl of Mutazyme II DNA
polymerase (Agilent Technologies, Santa Clara, CA). The para-
meters of the epPCR were as follows: one cycle at 95 1C for
5 min, followed by 30 cycles at 94 1C for 1 min, 50 1C for 1 min,
and 72 1C for 2 min, and then one cycle at 72 1C for 10 min. Site-
directed mutagenesis was performed by using the QuikChange II
Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA) accord-
ing to the manufacturer's instructions. In brief, the PCR mixture
included 36 μl of water, 5 μl of 10buffer, 1 μl of 2.5 mM
deoxyribonucleotide triphosphates, 2 μl of epPCR product
(25 ng/μl), 2 μl of hemagglutinin plasmid (10 ng/μl), and 1 μl
of PfuUltra High-Fidelity DNA Polymerase (Agilent Technologies,
Santa Clara, CA) (2.5 U/μl). After digestion with DpnI (a restric-
tion enzyme that only cleaves methylated DNA) at 37 1C for 1 h,
the PCR product (2 μl) was transfected into XL1-Blue Super-
competent Cells (Agilent Technologies, Santa Clara, CA). The
transformed cells were directly inoculated onto LB (Luria Ber-
tani) agar plates or into LB medium.
Generation of reassortant viruses by reverse genetics
The reassortant viruses were rescued by transfection in co-
cultured 293T cells and MDCK cells, as described elsewhere (Ye
et al., 2010), using mutated hemagglutinin gene, unmodiﬁed
neuraminidase gene of CA/04, and six internal genes from inﬂu-
enza A/PR/8/1934(H1N1) virus. At day 3 after transfection, the
media and cells were inoculated into 10-day-old eggs (0.2 ml/egg).
After 96 h inoculation , we collected the allantoic ﬂuids from the
eggs for viral titration.
Genomic sequencing
Virion RNA and cDNA were prepared as previously described
(Ye et al., 2010). Sequencing was performed at the Life Sciences
Core Laboratories Center at Cornell University (Ithaca, NY) by using
the automated 3730 DNA Analyzer (Applied Biosystems, Foster
City, CA), which utilizes Big Dye Terminator chemistry and
AmpliTaq-FS DNA Polymerase. Deep sequencing was performed
by the Beijing Genomics Institute (Shenzhen, China), using a MiSeq
sequencer (Illumina, Shanghai, China).
Growth kinetics in MDCK cells
To determine the growth kinetics of viruses, we inoculated the
MDCK cells with inﬂuenza virus at a multiplicity of infection of
0.001 TCID50 and incubated the cells in 5% CO2 at 37 1C for 1 h. The
inocula were removed and washed two times with phosphate-
buffered saline (PBS). The cells were then incubated (37 1C in 5%
CO2) in Opti-MEM I (GIBCO, Grand Island, NY) containing TPCK–
trypsin (1 mg/ml). At speciﬁed time points after inoculation, 200 ml
of supernatants were collected, aliquoted, and stored at 70 1C
until use. Virus titers in supernatants collected at the different
time points were determined by TCID50 in MDCK cells.
Western blot assay
The Western blot assay was used to compare the yields of the
vaccine candidates with those of the wild-type strain. The cell
supernatants were lysed and then analyzed by Western blot assay.
Western blots were developed by using horseradish peroxidase–
conjugated goat anti-mouse IgG (Santa Cruz Biotechnology, Santa
Cruz, CA) and an enhanced chemiluminescence detection system
(ECL GE Healthcare, Pittsburgh, PA) and then exposed to X-ray
ﬁlm. The primary antibodies used in the Western blot assay were
inﬂuenza nucleoprotein monoclonal antibodies from the Biode-
fense and Emerging Infections Research Resources Repository
(Manassas, VA).
Quantitative reverse transcription PCR (qRT-PCR)
qRT-PCR was used to determine the level of viral RNA in the
allantoic ﬂuid of eggs inoculated with an inﬂuenza virus. Viral RNA
(50 μl total) was isolated from 200 μl of sample by using a Gene
JET Viral RNA Puriﬁcation Kit (Thermo Fisher Scientiﬁc, Pittsburgh,
PA). Inﬂuenza virus–speciﬁc Primer Uni12 (50-AGCAAAAGCAGG-30)
and 10 μl of template RNA were used in the cDNA synthesis (total
volume of 25 μl); the cDNA synthesis was carried out using
SuperScript III Reverse Transcriptase (Invitrogen, Grand Island,
NY) according to the manufacturer's instructions. Primers
130loop_F and 190helix_R were used in the qPCR, which consisted
of 5 μl of Master Mix (Applied Biosystems, Foster City, CA), 500 nM
each primer, 2 μl of target cDNA, and sufﬁcient diethylpyrocarbo-
nate (DEPC)-treated water to make a volume of 10 μl. The cDNA
was ampliﬁed by 40 two-step PCR cycles (3 s at 95 1C for
denaturation of the DNA, 20 s at 60 1C for primer annealing and
extension). qPCR ampliﬁcations were measured by using the
Stratagene M3005P qPCR System (Agilent Technologies, Santa
Clara, CA). As a sample standard, we used the pHW 2000 plasmid
vector with the hemagglutinin gene of CA/04, which was serially
diluted 10-fold to generate the standard curve. The ampliﬁcation
results were shown as Log10 copies/μl.
Total protein quantiﬁcation
Viruses were puriﬁed from the allantoic ﬂuids of 11-day-old
embryonated chicken eggs by low-speed clariﬁcation (4000 rpm,
20 min, 4 1C) followed by ultracentrifugation through a cushion of
30–60% sucrose in a 70Ti rotor (Beckman Coulter, Fullerton,
California) (37,500 rpm, 3 h, 4 1C). The virus band was collected
and puriﬁed through a cushion of 30% sucrose in a 70Ti rotor
(37,500 rpm, 3 h, 4 1C). The virus pellet was resuspended in 200 ul
PBS and the total amount of puriﬁed virion proteins was deter-
mined by Quant-iTTM protein assay kit (Invitrogen, USA).
Mouse vaccination and challenge
To assess the antigenicity and protective efﬁcacy of high-
yield mutant viruses, we vaccinated a group of 6-week-old
female BALB/c mice (Harlan Laboratories, Indianapolis, IN) by
intramuscular administration of 128 hemagglutination (HA)
units (in 50-μl volumes) of a formaldehyde-inactivated vaccine
candidate, mutant number 81 (n¼10 mice) or mutant number
88 (n¼10 mice). Two weeks later, we administered a booster
vaccine. Mock-vaccinated mice (n¼10) received a volume of PBS
equal to the amount of vaccine administered to the vaccinated
mice. Five mice that were not vaccinated and not challenged
served as environmental controls. Two weeks after the booster
vaccination, mice were anesthetized and challenged by intra-
nasal inoculation with mouse-adapted CA/04 at 10 the 50%
lethal dose (LD50). Serum samples were collected from mice
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before challenge and tested by using an HA inhibition (HI) assay.
To determine lung virus titers, we euthanized three mice at day
4 after challenge. Lungs were homogenized and resuspended in
1 ml of sterile PBS, and virus titers were determined in MDCK
cells. The samples were also stained with hematoxylin and eosin
stain for pathologic examination. The survival rate, clinical
signs, and body weight of the remaining mice were monitored
for 14 days after the challenge. All animal studies were approved
by the Ofﬁce of Regulatory Compliance Institutional Biosafety
Committee and the Institutional Animal Care and Use Commit-
tee of Mississippi State University.
HA and HI assays
HA and HI assays were performed by using a 0.5% suspension of
turkey red blood cells as described in the WHO Manual on Animal
Inﬂuenza Diagnosis and Surveillance (http://www.who.int/csr/
resources/publications/inﬂuenza/whocdscsrncs20025rev.pdf).
Structural modeling
Crystal structures of the hemagglutinin protein (Protein Data-
bank [PDB] accession nos. 3LZG, 3UBN, and 3UBQ of the A(H1N1)
pdm09 virus and the binding sites of carbohydrates 60-Sialyl-N-
acetyllactosamine (6SLN) and 30-Sialyl-N-acetyllactosamine (3SLN)
to this protein were obtained from PDB (Xu et al., 2013). Structural
simulation of amino acid mutations was performed on the
hemagglutinin by using the FoldX platform with its empirical
force ﬁeld (Schymkowitz et al., 2005) with crystal waters under
the following conditions: temperature of 298 K, pH 7, 0.05 ion
strength. Chimera (Pettersen et al., 2004) was used to visualize the
binding structures and measure contact distances. PoseScore,
which was designed for ranking near-native ligand–protein inter-
acting structures (Fan et al., 2011), was used to estimate the
likeness of the protein–glycan binding avidities of the wild-type
and mutant to that of the native virus. The computational analysis
of mutation effects on HA–glycan bindings was focused on the
mutants with 133 (H3 numbering) location only because the other
mutations are not located in the receptor-binding sites of hemag-
glutinin and did not modify the PoseScores of the hemagglutinin
of the wild-type virus.
Accession numbers
The crystal structures of the hemagglutinin protein were
downloaded from Protein Data bank with accession numbers:
3LZG, 3UBN, and 3UBQ.
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